156 related articles for article (PubMed ID: 1533410)
21. OKT3 monoclonal antibody induces production of colony-stimulating factor(s) for granulocytes and macrophages in cultures of human T lymphocytes and adherent cells.
Platzer E; Rubin BY; Lu L; Welte K; Broxmeyer HE; Moore MA
J Immunol; 1985 Jan; 134(1):265-71. PubMed ID: 3917276
[TBL] [Abstract][Full Text] [Related]
22. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.
Bolt S; Routledge E; Lloyd I; Chatenoud L; Pope H; Gorman SD; Clark M; Waldmann H
Eur J Immunol; 1993 Feb; 23(2):403-11. PubMed ID: 8436176
[TBL] [Abstract][Full Text] [Related]
23. Synergistic effects of IL-7 and IL-12 on human T cell activation.
Mehrotra PT; Grant AJ; Siegel JP
J Immunol; 1995 May; 154(10):5093-102. PubMed ID: 7730615
[TBL] [Abstract][Full Text] [Related]
24. Human retinal pigment epithelial cell interleukin-8 and monocyte chemotactic protein-1 modulation by T-lymphocyte products.
Elner SG; Elner VM; Bian ZM; Lukacs NW; Kurtz RM; Strieter RM; Kunkel SL
Invest Ophthalmol Vis Sci; 1997 Feb; 38(2):446-55. PubMed ID: 9040478
[TBL] [Abstract][Full Text] [Related]
25. Anti-CD3 antibodies OKT3 and hOKT3gamma1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecifc T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells.
Popma SH; Griswold DE; Li L
Int Immunopharmacol; 2005 Jan; 5(1):155-62. PubMed ID: 15589476
[TBL] [Abstract][Full Text] [Related]
26. Induction of human monocyte IL-1 mRNA and secretion during anti-CD3 mitogenesis requires two distinct T cell-derived signals.
Landis RC; Friedman ML; Fisher RI; Ellis TM
J Immunol; 1991 Jan; 146(1):128-35. PubMed ID: 1824588
[TBL] [Abstract][Full Text] [Related]
27. Human T cell activation by OKT3 is inhibited by a monoclonal antibody to CD44.
Rothman BL; Blue ML; Kelley KA; Wunderlich D; Mierz DV; Aune TM
J Immunol; 1991 Oct; 147(8):2493-9. PubMed ID: 1833455
[TBL] [Abstract][Full Text] [Related]
28. Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4.
Richards J; Auger J; Peace D; Gale D; Michel J; Koons A; Haverty T; Zivin R; Jolliffe L; Bluestone JA
Cancer Res; 1999 May; 59(9):2096-101. PubMed ID: 10232594
[TBL] [Abstract][Full Text] [Related]
29. Expression of IFN regulatory factor family proteins in lymphocytes. Induction of Stat-1 and IFN consensus sequence binding protein expression by T cell activation.
Nelson N; Kanno Y; Hong C; Contursi C; Fujita T; Fowlkes BJ; O'Connell E; Hu-Li J; Paul WE; Jankovic D; Sher AF; Coligan JE; Thornton A; Appella E; Yang Y; Ozato K
J Immunol; 1996 May; 156(10):3711-20. PubMed ID: 8621906
[TBL] [Abstract][Full Text] [Related]
30. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
31. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
[TBL] [Abstract][Full Text] [Related]
32. Regional and systemic distribution of anti-tumor x anti-CD3 heteroaggregate antibodies and cultured human peripheral blood lymphocytes in a human colon cancer xenograft.
Nelson H; Ramsey PS; Kerr LA; McKean DJ; Donohue JH
J Immunol; 1990 Nov; 145(10):3507-15. PubMed ID: 1700013
[TBL] [Abstract][Full Text] [Related]
33. Induction of interleukin 2 receptiveness and proliferation in resting peripheral T cells by monoclonal anti-CD3 (T3) antibodies does not require the presence of macrophages.
Stingl LA; Sinska A; Landesmann U; Smolen JS
Clin Exp Immunol; 1987 Apr; 68(1):146-55. PubMed ID: 3115639
[TBL] [Abstract][Full Text] [Related]
34. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.
Yang SC; Owen-Schaub LB; Roth JA; Grimm EA
Cancer Res; 1990 Jun; 50(12):3526-32. PubMed ID: 2160321
[TBL] [Abstract][Full Text] [Related]
35. Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma.
Ellis JH; Barber KA; Tutt A; Hale C; Lewis AP; Glennie MJ; Stevenson GT; Crowe JS
J Immunol; 1995 Jul; 155(2):925-37. PubMed ID: 7608568
[TBL] [Abstract][Full Text] [Related]
36. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
[TBL] [Abstract][Full Text] [Related]
37. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
Demanet C; Brissinck J; Van Mechelen M; Leo O; Thielemans K
J Immunol; 1991 Aug; 147(3):1091-7. PubMed ID: 1830596
[TBL] [Abstract][Full Text] [Related]
38. Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B cells.
Lazdina U; Cao T; Steinbergs J; Alheim M; Pumpens P; Peterson DL; Milich DR; Leroux-Roels G; Sällberg M
J Virol; 2001 Jul; 75(14):6367-74. PubMed ID: 11413303
[TBL] [Abstract][Full Text] [Related]
39. Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody.
Chatterjee SK; Tripathi PK; Chakraborty M; Yannelli J; Wang H; Foon KA; Maier CC; Blalock JE; Bhattacharya-Chatterjee M
Cancer Res; 1998 Mar; 58(6):1217-24. PubMed ID: 9515808
[TBL] [Abstract][Full Text] [Related]
40. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
Tutt A; Stevenson GT; Glennie MJ
J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
